Boston Medical Sciences

What Boston Medical Sciences does

Boston Medical Sciences株式会社 is a Tokyo-based, venture-backed medical device company founded in April 2023 that is developing AIM4CRC, an AI-powered virtual colonoscopy (CT colonography) system designed to eliminate the need for laxative bowel preparation. The product combines two proprietary AI components — Virtual Bowel Cleansing AI, which digitally removes stool and fluid artifacts from CT scan data, and Polyp Detection AI, which identifies and segments colorectal lesions — and is, per company claims, the first system in the world to enable clinical implementation of high-accuracy, laxative-free full colon examination. Core AI technologies are patent-pending, and the company has secured FDA Breakthrough Device Designation (May 2026), FDA TAP Program acceptance (June 2026), and Japan's MHLW Priority SaMD designation (May 2024), along with a Class II Medical Device Marketing License and ISO/IEC 27001 certification. Boston Medical Sciences generates no revenue to date and is expected to commercialize through a B2B enterprise sales motion targeting hospitals, cancer centers, and screening clinics in Japan and the United States, supported by a joint venture (Boston Medical Diagnostics, established February 2026 with CUC Co., Ltd.) that provides remote diagnostic reading support services.

Name

Boston Medical Sciences

Legal name

Boston Medical Sciences株式会社

Website

https://b-ms.tech

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Boston Medical Sciences is a Tokyo-based, pre-revenue medical device company developing AIM4CRC, an AI-powered virtual colonoscopy system that enables laxative-free colorectal cancer screening using proprietary virtual bowel cleansing and polyp detection AI, targeting hospitals and screening clinics in Japan and the United States.

Ownership category

akta.pro rank

Product category

Medical Imaging AI / Diagnostic Software

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD)

Keywords

• Medical imaging AI
• Virtual colonoscopy
• Colorectal cancer screening
• Diagnostic AI software
• SaMD medical devices

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AIM4CRC System (Diagnostic AI Software): Pre-revenue. The company is developing and clinically implementing a non-invasive colorectal cancer screening AI system (AIM4CRC). Revenue generation model is not yet publicly disclosed but is expected to follow a medical device / SaaS model targeting healthcare institutions. The company has established a second-class medical device manufacturing and sales license and ISMS certification.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Boston Medical Sciences develops AIM4CRC, an AI-powered virtual colonoscopy (CT colonography) system that eliminates the need for laxative bowel preparation. The system combines proprietary Virtual Bowel Cleansing AI, which digitally cleans CT colonography images of stool and fluid artifacts, with Polyp Detection AI that identifies colorectal polyps and lesions. Targeted at hospitals, cancer centers, and screening clinics in Japan and the United States.

Product overview

Boston Medical Sciences offers a single flagship product system called AIM4CRC - a laxative-free virtual colonoscopy system that represents a groundbreaking approach to colorectal cancer screening. The system comprises two core AI components: Virtual Bowel Cleansing AI (which digitally removes stool and fluid from CT colonography images without requiring physical laxative preparation) and Polyp Detection AI (which identifies and segments colorectal polyps and abnormalities). The company has also established a subsidiary, Boston Medical Diagnostics, to provide remote diagnostic reading support services, expanding beyond the core product into service offerings.

Differentiator

Problem solved

Functional benefit

Brands

• AIM4CRC: AI-powered laxative-free virtual colonoscopy system for colorectal cancer screening. Uses virtual bowel cleansing AI and polyp detection AI for non-invasive colon examination.
• Boston Medical Diagnostics (ボストン �

Products and services

• AIM4CRC Virtual Endoscopy System AI-powered laxative-free virtual colonoscopy (CT colonography) system for non-invasive colorectal cancer screening. Combines Virtual Bowel Cleansing AI, which digitally cleans the colon from CT scan data by removing stool and fluid artifacts without physical laxative preparation, with Polyp Detection AI that identifies and segments colorectal polyps and lesions. Targeted at hospitals, cancer centers, and screening clinics in Japan and the United States.
• Boston Medical Diagnostics (Remote Diagnostic Reading Support Services) Joint venture providing remote diagnostic reading support services for medical institutions. Boston Medical Sciences contributes AI imaging analysis technology and CUC contributes healthcare institution support services, enabling AI-assisted diagnostic reading services for partner hospitals and clinics.

Quantifiable outcome

• First-in-world laxative-free full colon examination clinically implemented
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Tokushukai Group (Kitatani Hospital)coreStrategic or Co-development Partner · 22 June 2026Joint research with Tokushukai Group's Kitatani Hospital on colorectal CT examination AI, focusing on accuracy improvement and clinical utility evaluation of Boston Medical Sciences' core AI technology. Hospital scheduled to relocate and rename to Cozartoku Tokushukai Hospital in 2027.
• CUC Co., Ltd. (株式会社シーユーシー)coreStrategic or Co-development Partner · 5 February 2026Joint venture to establish Boston Medical Diagnostics (ボストン メディカ儿 ダイアグノスティクス) for providing remote diagnostic reading support services. CUC contributes healthcare institution support services; Boston Medical Sciences contributes AI imaging analysis technology.
• Harvard Medical School / Massachusetts General Hospital 3D Imaging ResearchcoreStrategic or Co-development PartnerWorld-leading academic and clinical research institution collaboration for imaging research and international joint research on AI-powered CT colonography. The company's founder serves as an instructor in Radiology at Harvard Medical School and staff researcher at MGH.
• National Cancer Center Hospital (Diagnostic Radiology Department)minorStrategic or Co-development PartnerDr. Yuto Okawa, Director at Boston Medical Sciences, serves as a visiting researcher at National Cancer Center Hospital's Diagnostic Radiology Department, supporting academic collaboration and research validation.
• University of Occupational and Environmental Health, Japan (Center for Research of the Aging Workforce)minorStrategic or Co-development PartnerDr. Yuto Okawa serves as a part-time lecturer, supporting academic collaboration and research network expansion.
• University of Tsukuba (Department of Psychiatry)minorStrategic or Co-development PartnerDr. Yasunori Yamada, CSO at Boston Medical Sciences, serves as a visiting researcher, supporting research collaboration.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• HeartFlow: US-based AI SaMD company that analyzes CT imaging (coronary CT angiography) to support clinical decision-making. Closest comparable in business model: AI software analyzing CT scans for diagnostic support, with FDA-cleared SaMD product, US market focus, and recurring per-scan economics.
• Viz.ai: US-based AI imaging SaMD company with FDA-cleared algorithms for stroke detection from CT imaging. Comparable as an AI-first imaging SaMD targeting specialist clinical workflows with workflow-integrated diagnostic support, similar regulatory pathway approach, and recurring revenue per analysis.
• LPIXEL: Tokyo-based AI medical imaging company that developed EIRL, a deep-learning-based diagnostic imaging support software approved as a medical device in Japan. Most direct Japanese peer in AI medical imaging SaMD, and notably the strategic advisor Yuki Shimahara is LPIXEL's founder.
• Iterative Health: AI-driven gastroenterology company applying machine learning to endoscopic imaging for IBD and CRC detection. Directly comparable focus on AI in GI imaging and CRC-related clinical workflows, serving the same gastroenterologist customer base that BMS targets through virtual colonoscopy.
• Paige.AI: AI pathology company with FDA-authorized SaMD for cancer detection in pathology images. Comparable as a venture-backed AI diagnostic SaMD with FDA authorization, focusing on oncology detection using deep learning and serving hospital pathology workflows.

Broad incumbents

• Canon Medical Systems: Japanese-headquartered medical imaging incumbent with CT systems and growing AI imaging software offerings. Most directly comparable large imaging vendor operating in BMS's home Japanese market and serving the same hospital customers, with potential to integrate competing AI capabilities.
• GE HealthCare: Global medical imaging and diagnostics incumbent with CT colonography capabilities and active AI imaging portfolio. BMS has prior team member relationships with GE HealthCare and notes it as a reference institution for CT imaging technology collaboration. Represents both potential partner and broad incumbent competitor.
• RadNet: US operator of outpatient diagnostic imaging centers and developer of AI-enhanced imaging workflows. Comparable business segment in diagnostic imaging services and AI-augmented radiology, though operating at much larger scale as an incumbent imaging services provider.
• Olympus: Japanese-headquartered global leader in endoscopy systems including colonoscopy. Indirect incumbent competition: Olympus's installed base of conventional colonoscopy systems represents the workflow that AIM4CRC aims to substitute or complement for CRC screening, making it a strategic threat or partner depending on Olympus's response to virtual colonoscopy AI.
• FUJIFILM: Japanese conglomerate with healthcare imaging and AI-enabled diagnostic offerings including endoscopy and radiology IT. Comparable as a Japanese-headquartered incumbent with both imaging hardware and AI imaging software capabilities serving similar hospital customers in the Japanese market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boston Medical Sciences